Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing

Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · Aug 11, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new way to evaluate how well treatments are working for patients with aggressive B-cell lymphoma, specifically a type called large B-cell lymphoma (LBCL). The researchers want to see if analyzing small pieces of tumor DNA found in the blood (called circulating tumor DNA or ctDNA) can provide more accurate information about a patient’s response to treatment compared to traditional imaging methods like CT and PET scans. By using advanced DNA testing technologies, the trial aims to determine if tracking ctDNA levels during treatment can help doctors assess whether the treatment is effective or if the cancer is returning.

To participate in this trial, individuals must be at least 18 years old and have a confirmed diagnosis of aggressive B-cell lymphoma. There are no specific exclusion criteria, so most patients with this diagnosis may qualify. Participants can expect to provide blood samples for ctDNA analysis during their treatment, which will help researchers learn more about the effectiveness of this approach. Overall, this study aims to improve the way doctors monitor treatment response, potentially leading to safer and more effective care for patients with lymphoma.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • • Pathology proven lymphoma
• • Age ≥ 18 years old
• Exclusion Criteria:
• • none